Fierce Pharma Asia—Akeso, Summit’s Keytruda-beating data; BIOSECURE’s House passage; Candid’s $370M debut

Fierce Pharma September 13, 2024
Angus Liu

Akeso and Summit Therapeutics’ ivonescimab showed strong efficacy against Merck’s Keytruda in a phase 3 trial in China. The BIOSECURE Act sailed through a full House vote despite some objections. Candid Therapeutics amassed $370 million in series A funds with two T-cell engagers licensed from China. And more.

1. Akeso, Summit’s PD-1 bispecific crushes Merck’s Keytruda in study, signaling potential new standard in lung cancer

Akeso and Summit Therapeutics’ PD-1/VEGF bispecific ivonescimab cut the risk of disease progression or death by 49% over Merck’s Keytruda in a Chinese phase 3 trial in first-line PD-L1-positive non-small cell lung cancer. Consistent benefits were seen across key patient subgroups. While the drug showed strong data, it still has some proving to do before...

Today's Sponsors

Today's Sponsor